ArticleThe Journal of dermatology2024

Long-term follow-up results from KEYNOTE-041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma.

Kenji Yokota et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.